Using Metabolic Biomarkers to Predict Risk for Postpartum Depression
Metabolic biomarkers in the cerebrospinal fluid may be used to identify women at high risk for postpartum depression.
Metabolic biomarkers in the cerebrospinal fluid may be used to identify women at high risk for postpartum depression.
Compared to individuals with histories of psychiatric illness prior to pregnancy, perinatal individuals without a prepregnancy psychiatric history were less likely to be screened, referred, and treated for depression.
Psychological interventions may reduce the severity of perinatal anxiety symptoms.
ADHD is an important risk factor for both depression and anxiety disorders in the postpartum period and should be considered in the post-pregnancy maternal care.
There is evidence that screening for perinatal mood and anxiety disorders may improve outcomes; however, success depends on adequate resources for screening, diagnosis, treatment and follow-up.
Postpartum women taking a drospirenone-only contraceptive pill experienced a decrease in depressive symptoms.
Intravenous ketamine or esketamine given at the time of cesarean delivery reduced risk for postpartum depression; predictive models are needed to determine which women are most likely to benefit from this intervention.
Addressing sleep problems may be an important component of suicide prevention efforts, as improving sleep quality and duration may help to reduce the risk of suicide in perinatal population.
Evidence suggests that sleep disturbance during pregnancy is associated with higher risk of perinatal depression, especially during the third trimester.
This very helpful list from Wendy Davis, PhD, Executive Director of Postpartum Support International, describes what the various emergency services can provide.